Sign Up to like & get
recommendations!
0
Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-127
Abstract: In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer.
read more here.
Keywords:
durvalumab lengthens;
extensive stage;
durvalumab;
survival extensive ... See more keywords